Affibody-based molecular probe

99mTc SPECT imaging affibody human epidermal growth factor receptor 2 ovarian cancer

Journal

Open medicine (Warsaw, Poland)
ISSN: 2391-5463
Titre abrégé: Open Med (Wars)
Pays: Poland
ID NLM: 101672167

Informations de publication

Date de publication:
2024
Historique:
received: 18 04 2024
revised: 25 07 2024
accepted: 09 08 2024
medline: 9 9 2024
pubmed: 9 9 2024
entrez: 9 9 2024
Statut: epublish

Résumé

This study aimed to assess the biodistribution and bioactivity of the affibody molecular probe Affibody molecules were generated through genetic recombination. The radiochemical purity of the Affibody (HE) The molecular probe

Identifiants

DOI: 10.1515/med-2024-1027 PMID: 39247440 PMC: PMC11377979
pubmed: 39247440
doi: 10.1515/med-2024-1027
pii: med-2024-1027
pmc: PMC11377979
doi:

Types de publication

Journal Article

Langues

eng

Pagination

20241027

Informations de copyright

© 2024 the author(s), published by De Gruyter.

Déclaration de conflit d'intérêts

Conflict of interest: The authors declare that they have no competing interests.

Auteurs

Xianwen Hu (X)

Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, Huichuan, Zunyi, 563003, China.

Hongyu Hu (H)

Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, Huichuan, Zunyi, 563003, China.

Dandan Li (D)

Department of Obstetrics, Zunyi Hospital of Traditional Chinese Medicine, Zunyi, Guizhou, Zunyi, 563003, China.

Pan Wang (P)

Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, China.

Jiong Cai (J)

Department of Nuclear Medicine, Affiliated Hospital of Zunyi Medical University, 149 Dalian Road, Huichuan, Zunyi, 563003, China.

Classifications MeSH